

Recommendations of the SEC (Oncology & Hematology) made in its 157th meeting held on 14.09.2023 at CDSCO (HQ), New Delhi:

S. No.	File Name & Drug Name, Strength	Firm Name	Recommendations
GCT Division			
1.	CT/74/18	M/s AstraZeneca	<p>The firm presented their proposal for protocol amendment vide protocol No. D933QC00001, Amendment Version 5.0 dated 10 Jan 2023 before the committee.</p> <p>After detailed deliberation, the committee recommended for approval of the proposed amendment as presented by the firm.</p>
2.	CT/29/21	M/s Bayer Pharmaceuticals	<p>The firm presented their proposal for protocol amendment vide protocol No. 20289, Amendment Version 13 dated 03 Mar 2023 before the committee.</p> <p>After detailed deliberation, the committee recommended for approval of the proposed amendment as presented by the firm.</p>
3.	CT/46/22	M/s AstraZeneca	<p>The firm presented their proposal for protocol amendment vide protocol No. D926PC00001, Amendment-2 Version 3.0 dated 11 April 2023 before the committee.</p> <p>After detailed deliberation, the committee recommended for approval of the proposed amendment as presented by the firm.</p> <p>Dr. C.K. Bose did not participate in the deliberation.</p>